US big biopharma companies reported steady first quarter sales growth, but for several drug makers, sales of COVID-19 vaccines and treatments powered that growth. While the revenue boost is welcomed by investors, uncertainty around the evolving pandemic and the long-term outlook for the franchises means drug makers need to show their core businesses are also on a solid footing.
A mounting overhang for the big pharma sector in general is loss of exclusivities (LOE) for key drugs that are...